Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization
- Gill C. M.
- Aktas E.
- Alfouzan W.
- Bourassa L.
- Brink A.
- Burnham C. -A. D.
- Canton R.
- Carmeli Y.
- Falcone M.
- Kiffer C.
- Marchese A.
- Martinez O.
- Pournaras S.
- Seifert H.
- Thabit A. K.
- Villegas M. V.
- Westblade L. F.
- Nicolau D. P.
- Wille J.
- Rezende T. T. F.
- Cekin Z.
- Malkocoglu G.
- Gijon D.
- Tarakmeh L. A.
- Chu C. Y.
- Opperman C. J.
- Tootla H. D.
- Moodley C.
- Coetzee J.
- Vourli S.
- Dimopoulos G.
- Attallah D. M.
- Tiseo G.
- Leonildi A.
- Giordano C.
- Barnini S.
- Menichetti F.
- Di Pilato V.
- Codda G.
- Vena A.
- Giacobbe D. R.
- Satlin M.
- Cardona A.
- Curtis L.
- Fang F.
- Thomson G.
- Thomson K.
Publication date
January 2021
DOIAbstract
The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints
Add to ORKG